DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
UPDATE STATEMENT

A toxicological Profile for PCBs, Draft for Public Comment, was released in December 1998. This edition supercedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary, but no less than once every three years.

For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance’s toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance’s relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance’s health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and Disease Registry
*Legislative Background*

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children

Other Sections of Interest:

Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 639-6357    Fax: (404) 639-6359
E-mail: atsdric@cdc.gov    Internet: http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. **Contact:** NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. **Contact:** NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. **Contact:** NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. **Contact:** AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: [http://oec-env-med.mc.duke.edu/oem/aoec.htm](http://oec-env-med.mc.duke.edu/oem/aoec.htm).

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. **Contact:** ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Obaid Faroon, Ph.D.
ATSDR, Division of Toxicology
Atlanta, Georgia

Syracuse Research Corporation
Environmental Science Center
North Syracuse, New York

James Olson, Ph.D.
University at Buffalo
Buffalo, New York

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:


2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

4. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
A peer review panel was assembled for polychlorinated biphenyls (PCBs). The panel consisted of the following members:

1. Larry Hansen, University of Illinois, College of Veterinary Medicine, Urbana, Illinois;
2. Joseph Jacobson, Wayne State University, Detroit, Michigan;
3. Helen Tryphonas, Bureau of Chemical Safety, Frederick G. Banting Research Center, Ottawa, Ontario, Canada;
4. John Vena, University at Buffalo, Social and Preventive Medicine, Buffalo, New York

These experts collectively have knowledge of PCBs physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.
# CONTENTS

FOREWORD .......................................................................................................................... v

QUICK REFERENCE FOR HEALTH CARE PROVIDERS ...................................................... vii

CONTRIBUTORS ................................................................................................................. ix

PEER REVIEW ...................................................................................................................... xi

LIST OF FIGURES ................................................................................................................ xix

LIST OF TABLES .................................................................................................................. xxi

1. PUBLIC HEALTH STATEMENT ......................................................................................... 1
   1.1 WHAT ARE POLYCHLORINATED BIPHENYLs? .............................................................. 1
   1.2 WHAT HAPPENS TO POLYCHLORINATED BIPHENYLs WHEN THEY ENTER THE ENVIRONMENT? ............................................................................................................. 2
   1.3 HOW MIGHT I BE EXPOSED TO POLYCHLORINATED BIPHENYLs? ......................... 3
   1.4 HOW CAN POLYCHLORINATED BIPHENYLs ENTER AND LEAVE MY BODY? ....... 5
   1.5 HOW CAN POLYCHLORINATED BIPHENYLs AFFECT MY HEALTH? ....................... 5
   1.6 HOW CAN POLYCHLORINATED BIPHENYLs AFFECT CHILDREN? ......................... 7
   1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO POLYCHLORINATED BIPHENYLs? ............................................................. 9
   1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO POLYCHLORINATED BIPHENYLs? .............................................. 10
   1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .......................................................... 11
   1.10 WHERE CAN I GET MORE INFORMATION? ............................................................... 12

2. RELEVANCE TO PUBLIC HEALTH ................................................................................... 15
   2.1 Background and Environmental Exposures to PCBs in the United States ................ 15
   2.2 Summary of Health Effects ....................................................................................... 16
   2.3 Minimal Risk Levels .................................................................................................. 27

3. HEALTH EFFECTS ............................................................................................................ 33
   3.1 INTRODUCTION ........................................................................................................... 33
   3.2 DISCUSSION OF HEALTH EFFECTS .......................................................................... 90
      3.2.1 Death .................................................................................................................... 90
         3.2.1.1 Human Studies .............................................................................................. 90
         3.2.1.2 Animal Studies ............................................................................................ 90
      3.2.2 Systemic Effects .................................................................................................. 92
         3.2.2.1 Respiratory ................................................................................................... 92
            3.2.2.1.1 Human Studies .................................................................................... 92
            3.2.2.1.2 Animal Studies ................................................................................... 94
         3.2.2.2 Cardiovascular .............................................................................................. 94
            3.2.2.2.1 Human Studies .................................................................................... 94
            3.2.2.2.2 Animal Studies ................................................................................... 96
3.2.2.3 Gastrointestinal ............................................. 97
  3.2.2.3.1 Human Studies ..................................... 97
  3.2.2.3.2 Animal Studies .................................. 98
3.2.2.4 Hematological .............................................. 99
  3.2.2.4.1 Human Studies ..................................... 99
  3.2.2.4.2 Animal Studies .................................. 100
3.2.2.5 Musculoskeletal ............................................ 102
  3.2.2.5.1 Human Studies .................................... 102
  3.2.2.5.2 Animal Studies .................................... 102
3.2.2.6 Hepatic Effects ............................................ 103
  3.2.2.6.1 Summary ......................................... 103
  3.2.2.6.2 Human Studies .................................... 103
    3.2.2.6.2.1 Liver Enzymes, Enlargement, and Pathology .... 103
    3.2.2.6.2.2 Serum Lipids, Triglycerides, and Cholesterol ... 106
    3.2.2.6.2.3 Porphyrria .................................. 108
    3.2.2.6.2.4 Evaluation of Human Studies .................. 108
  3.2.2.6.3 Animal Studies .................................... 110
    3.2.2.6.3.1 Liver Enzymes, Enlargement, and Pathology .... 110
    3.2.2.6.3.2 Serum Lipids, Triglycerides, and Cholesterol ... 116
    3.2.2.6.3.3 Porphyrria .................................. 118
    3.2.2.6.3.4 Other Hepatic Effects ......................... 119
    3.2.2.6.3.5 Evaluation of Animal Studies .................. 119
3.2.2.7 Renal Effects .............................................. 120
  3.2.2.7.1 Human Studies .................................... 120
  3.2.2.7.2 Animal Studies .................................... 120
3.2.2.8 Endocrine Effects ......................................... 122
  3.2.2.8.1 Summary ......................................... 122
  3.2.2.8.2 Human Studies .................................... 123
  3.2.2.8.3 Animal Studies .................................... 126
3.2.2.9 Dermal Effects ............................................. 136
  3.2.2.9.1 Summary ......................................... 136
  3.2.2.9.2 Human Studies .................................... 136
    3.2.2.9.2.1 Occupational Exposure ....................... 136
    3.2.2.9.2.2 Accidental Exposure ......................... 137
    3.2.2.9.2.3 Evaluation of Human Studies ................. 138
  3.2.2.9.3 Animal Studies .................................... 139
  3.2.2.9.4 Evaluation of Animal Studies .................... 140
3.2.2.10 Ocular Effects ............................................. 141
  3.2.2.10.1 Summary ......................................... 141
  3.2.2.10.2 Human Studies .................................... 141
    3.2.2.10.2.1 Occupational Exposure ....................... 141
    3.2.2.10.2.2 Accidental Exposure ......................... 142
    3.2.2.10.2.3 Evaluation of Human Studies ................. 142
  3.2.2.10.3 Animal Studies .................................... 143
  3.2.2.10.4 Evaluation of Animal Studies .................... 144
3.2.2.11 Body Weight Effects ..................................... 144
  3.2.2.11.1 Human Studies .................................... 144
  3.2.2.11.2 Animal Studies .................................... 144
3.2.2.12 Other Systemic Effects .................................. 146

3.2.3 Immunological and Lymphoreticular Effects ............................. 146
  3.2.3.1 Summary ............................................... 146
3.2.3.2 Human Studies .................................................. 147
3.2.3.3 Animal Studies .................................................. 153
  3.2.3.3.1 Inhalation Exposure ........................................... 153
  3.2.3.3.2 Oral Exposure ................................................ 153
  3.2.3.3.3 Dermal Exposure .............................................. 161
  3.2.3.3.4 Other Routes of Exposure .................................. 161
  3.2.3.3.5 Evaluation of Animal Studies .............................. 162
3.2.4 Neurological Effects ............................................ 165
  3.2.4.1 Summary ....................................................... 165
  3.2.4.2 Human Studies .................................................. 166
    3.2.4.2.1 Neurobehavioral Effects ................................ 166
      3.2.4.2.1.1 Contaminated Fish Consumption .................... 166
      3.2.4.2.1.2 General Population Exposure ....................... 173
      3.2.4.2.1.3 Occupational Exposure .............................. 182
      3.2.4.2.1.4 Accidental Exposure ................................ 183
    3.2.4.2.2 Neurophysiological Effects .............................. 184
    3.2.4.2.3 Evaluation of Human Studies ............................ 184
  3.2.4.3 Animal Studies .............................................. 188
    3.2.4.3.1 Neurobehavioral Effects ................................ 188
    3.2.4.3.2 Neurochemical Effects .................................. 195
    3.2.4.3.3 Other Neurological Effects .............................. 198
    3.2.4.3.4 Evaluation of Animal Studies .......................... 199
3.2.5 Reproductive Effects ........................................... 202
  3.2.5.1 Summary ....................................................... 202
  3.2.5.2 Human Studies .................................................. 203
    3.2.5.2.1 Female Reproductive Effects ............................ 203
    3.2.5.2.2 Male Reproductive Effects ................................ 209
    3.2.5.2.3 Evaluation of Human Studies ............................ 212
  3.2.5.3 Animal Studies .............................................. 215
    3.2.5.3.1 Female Reproductive Effects ............................ 215
    3.2.5.3.2 Male Reproductive Effects .............................. 222
    3.2.5.3.3 Evaluation of Animal Studies .......................... 225
3.2.6 Developmental Effects .......................................... 227
  3.2.6.1 Summary ....................................................... 227
  3.2.6.2 Human Studies .................................................. 229
    3.2.6.2.1 Growth and Development ................................ 229
      3.2.6.2.1.1 Contaminated Fish Consumption .................... 229
      3.2.6.2.1.2 General Population Exposure ....................... 234
      3.2.6.2.1.3 Occupational Exposure .............................. 237
      3.2.6.2.1.4 Accidental Exposure ................................ 238
    3.2.6.2.2 Evaluation of Human Studies ............................ 238
  3.2.6.3 Animal Studies .............................................. 241
    3.2.6.3.1 Birth Weight and Early Development .................... 241
    3.2.6.3.2 Evaluation of Animal Studies .......................... 245
3.2.7 Genotoxic Effects ................................................ 246
  3.2.7.1 Summary ....................................................... 246
  3.2.7.2 In Vivo Studies ................................................ 246
  3.2.7.3 In Vitro Studies ................................................ 249
  3.2.7.4 Evaluation of Genotoxicity Studies ......................... 249
3.2.8 Cancer ............................................................. 251
  3.2.8.1 Summary ....................................................... 251
3.2.8.2 Human Studies ............................................ 251
  3.2.8.2.1 Liver, Biliary Tract, and Gall Bladder ............ 251
  3.2.8.2.2 Gastrointestinal Tract ............................. 256
  3.2.8.2.3 Rectum ............................................... 257
  3.2.8.2.4 Skin ................................................... 258
  3.2.8.2.5 Brain and Central Nervous System ................. 261
  3.2.8.2.6 Hematological ...................................... 262
  3.2.8.2.7 Breast ............................................... 264
  3.2.8.2.8 Other Sites ......................................... 269
  3.2.8.2.9 Evaluation of Human Studies ....................... 271

3.2.8.3 Animal Studies ........................................... 275
  3.2.8.3.1 Inhalation Exposure .................................. 275
  3.2.8.3.2 Oral Exposure ....................................... 275
  3.2.8.3.3 Dermal Exposure ..................................... 282
  3.2.8.3.4 Evaluation of Animal Studies ....................... 283

3.3 HEALTH EFFECTS IN WILDLIFE POTENTIALLY RELEVANT TO HUMAN
  HEALTH ............................................................ 285
  3.3.1 Overview ................................................... 285
  3.3.2 Health Effects in Wildlife ................................ 290

3.4 TOXICOKINETICS .................................................. 295
  3.4.1 Absorption .................................................. 296
    3.4.1.1 Inhalation Exposure .................................. 296
    3.4.1.2 Oral Exposure ......................................... 297
    3.4.1.3 Dermal Exposure ....................................... 302
  3.4.2 Distribution ................................................ 305
    3.4.2.1 Inhalation Exposure .................................. 311
    3.4.2.2 Oral Exposure ......................................... 312
    3.4.2.3 Dermal Exposure ....................................... 315
    3.4.2.4 Other Routes of Exposure .............................. 315
  3.4.3 Metabolism ................................................. 316
  3.4.4 Elimination and Excretion ................................ 322
    3.4.4.1 Inhalation Exposure .................................. 322
    3.4.4.2 Oral Exposure ......................................... 322
    3.4.4.3 Dermal Exposure ....................................... 334
    3.4.4.4 Other Routes of Exposure .............................. 334
  3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 336
    3.4.5.1 Summary of the PBPK Model ........................... 337
    3.4.5.2 Description of the Model ............................. 339
    3.4.5.3 Discussion of the Model .............................. 340
    3.4.5.4 Validation of the Model .............................. 345
    3.4.5.5 Prediction of Congener Specific PBPK Model Parameters. 346

3.5 MECHANISMS OF ACTION ........................................ 348
  3.5.1 Pharmacokinetic Mechanisms ............................. 348
  3.5.2 Mechanisms of Toxicity ................................... 352
  3.5.3 Animal-to-Human Extrapolations ........................ 370

3.6 ENDOCRINE DISRUPTION .......................................... 372

3.7 CHILDREN’S SUSCEPTIBILITY ................................... 380

3.8 BIOMARKERS OF EXPOSURE AND EFFECT ........................ 394
  3.8.1 Biomarkers Used to Identify or Quantify Exposure to Polychlorinated Biphenyls 395
  3.8.2 Biomarkers Used to Characterize Effects Caused by Polychlorinated Biphenyls 399

3.9 INTERACTIONS WITH OTHER CHEMICALS .......................... 401
9. REFERENCES ................................................................. 627
10. GLOSSARY ................................................................. 759

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS ......................... A-1
   Table A1. ........................................................ A-10
   Table A2. ........................................................ A-14
B. USER’S GUIDE .......................................................... B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ................................. C-1
D. INDEX ................................................................ D-1
E. SUMMARY REPORT FOR THE EXPERT PANEL REVIEW of April 13, 2000 .... E-1
LIST OF FIGURES

3-1  Levels of Significant Exposure to PCB Mixtures - Inhalation ............................ 42
3-2  Levels of Significant Exposure to PCB Mixtures - Oral ................................ 78
3-3  Metabolic Pathways for Polychlorinated Biphenyls .................................... 323
3-4  Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance ......................... 338
3-5  Existing Information on Health Effects of Polychlorinated Biphenyls ............... 415
6-1  Frequency of NPL Sites with PCB Contamination ........................................... 478
6-2  Pathways for OH Radical-initiated Reaction of 3-Chlorobiphenyl ..................... 505
6-3  Pathways for Aerobic Degradation of PCBs ................................................ 509
6-4  Possible Mechanism for Reductive Dechlorination by Anaerobic Microorganisms . 515
6-5  1998 Fish Advisories for Polychlorinated Biphenyls ...................................... 582
LIST OF TABLES

3-1  Levels of Significant Exposure to PCBs - Inhalation ................................................. 39
3-2  Levels of Significant Exposure to PCBs - Oral ........................................................... 43
3-3  Levels of Significant Exposure to PCBs - Dermal ....................................................... 88
3-4  Genotoxicity of Polychlorinated Biphenyls In Vivo ...................................................... 248
3-5  Genotoxicity of Polychlorinated Biphenyls In Vitro ...................................................... 250
3-6. PCB Hazard Identification in Wildlife .............................................................................. 287
3-7. Net Gastrointestinal Absorption or Excretion of PCBs in Humans and Dependence on Congener-Specific Blood Lipid Levels .......................................................... 300
3-8. Mean PCB Concentrations (Microgram Per Kilogram Lipid Basis) in Autopsy Tissue Samples from Greenlanders .................................................................................. 310
3-9. Apparent Half-lives (Years) of PCB Congeners from Multiple Studies ......................... 326
3-10. Apparent Half-lives (Years) of PCB Mixtures from Multiple Studies ............................ 328
3-11. Volumes and Flow Rates in Several Tissues of Four Species ....................................... 341
3-12. Metabolism Rate Constant (k) from the Physiologic Model ........................................... 342
3-13. Tissue-to-blood Distribution Coefficients for Parent Polychlorinated Biphenyls (R) and Metabolites (R’) ........................................................................................................ 343
3-14. Kidney Clearance (kₖ) and Biliary Clearance (k₇) for Selected Polychlorinated Biphenyls in Several Species .................................................................................................................. 344
3-15. Ongoing Studies on the Health Effects of PCBs .............................................................. 436
3-16. Ongoing Studies on the Human Health Effects of PCBs Sponsored by ATSDR ............... 441
4-1. Chemical Identity of Selected Technical Polychlorinated Biphenyls or Aroclors ............. 445
4-2. Chemical Identity of Polychlorinated Biphenyl Congeners and Homologs .......................... 447
4-3. Physical and Chemical Properties of Some Aroclors ....................................................... 453
4-4. Approximate Weight Percent of PCB Homologs in Some Aroclors ................................. 456
4-5. Polychlorinated Biphenyl Congener Compositions (in Weight Percent)* in Aroclors ........ 457
4-6. Concentrations of Chlorinated Dibenzofurans (CDFs) in Commercial Polychlorinated Biphenyl Mixtures ................................................................. 465

4-7. Physical and Chemical Properties of Several Congeners of Polychlorinated Biphenyls .... 466

5-1. Summary of Former End Uses for Various Aroclors ................................................... 470

5-2. Facilities that Manufacture or Process Polychlorinated Biphenyls ................................ 472

6-1. Releases to the Environment from Facilities that Manufacture or Process Polychlorinated Biphenyls ................................................................. 484

6-2. Percentage of Loss of Polychlorinated Biphenyls from the Great Lakes Waters .............. 492

6-3. Bioconcentration Factors (BCFs) and Bioaccumulation Factors (BAFs) for Select Congeners and Total Polychlorinated Biphenyls in Various Aquatic Organisms ......................................................... 494

6-4. Bioconcentration Factors (BCFs) for Various Aroclors in Fresh Water Species ............... 495

6-5. Bioconcentration Factors (BCFs) for Various Aroclors in Salt Water Species .................. 496

6-6. Field Measured Bioaccumulation Factors for Isomeric Groups of Polychlorinated Biphenyls ................................................................. 498

6-7. Observed Soil and Sediment Sorption Coefficients (Koc) for Polychlorinated Biphenyls Congeners ........................................................................ 500

6-8. Plant Uptake (Bioaccumulation) of PCBs .................................................................... 503

6-9. Positions of Chlorines Removed by Each Dechlorination Process ................................. 513

6-10. Atmospheric Concentrations of Polychlorinated Biphenyls ........................................ 522

6-11. PCB Concentrations in Water Samples Collected from the Great Lakes ......................... 529

6-12. Comparison of PCB Levels (ng/L) in Rainwater Samples from the 1970s to the 1990s ...... 531

6-13. Polychlorinated Biphenyl Residues in Domestic Raw Foods for Fiscal Years 1969–1976 ... 537

6-14. Mean PCB Concentrations in Fish from the Great Lakes Region .................................... 542

6-15. Mean PCB Concentrations in Fish ............................................................................ 543

6-16. Mean Total PCB Levels in Standard Fillets of Fish Collected from the Vicinity of a Superfund Site ........................................................................ 546

6-17. Mean PCB Concentrations in Fish from Remote Areas .............................................. 548

6-18. Mean Concentration of PCBs in Crustaceans ............................................................ 550

6-19. Mean PCB Concentrations in Animals ..................................................................... 552
6-20. Mean PCB Concentrations in Blubber of Sea Mammals .................................................. 554


6-22. Estimated Daily Dietary Intake (µg/kg/day) of Polychlorinated Biphenyls for Adults, Toddlers, and Infants ............................................................................................................. 561

6-23. Mean Daily Intakes of PCBs Per Unit of Body Weight (µg/kg body weight/day) ............. 562


6-25. Adult Total Diet Studies — PCB Intakes from 265 Foods for the Years 1991–1997 ......... 564

6-26. Serum Polychlorinated Biphenyl (PCB) Levels in Populations with Occupational Exposure .................................................................................................................. 567

6-27. Mean Concentration of PCBs in Human Breast Milk ....................................................... 571


6-29. Ongoing Studies on Environmental Fate and Treatment of Polychlorinated Biphenyls .... 593

7-1. EPA Method 1668-Estimated Method Detection Limits (EMDL) and Estimated Minimal Levels (EML) of Selected PCB Congeners ........................................................................ 598

7-2. Analytical Methods for Determining Polychlorinated Biphenyls in Biological Samples ................................. 599

7-3. Analytical Methods for Determining Polychlorinated Biphenyls in Environmental Samples .......................... 604

7-4. NIST Standard Reference Materials for the Determination of Polychlorinated Biphenyls (PCBs) .......................................................................................................................... 610

7-5. Analytical Methods for Determining Biomarkers for Polychlorinated Biphenyls ............. 611

8-1. Regulations and Guidelines Applicable to PCBs .................................................................. 619